Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

MADISON, Wis., May 22, 2025--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended ...

MADISON, Wis., May 01, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million ...

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2 ...

A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part due to a focus on consumerization.

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Exact Sciences has achieved significant growth over the past five years. However, its bottom line remains deep in the red. The cancer diagnostic company is cash-flow negative. Would investing in ...

Exact Sciences is a major holding in both Cathie's ARK Innovation ETF and ARK Genomic Revolution ETF. Find out why I will plan on maintaining an EXAS position through 2027.

Exact Sciences is also developing blood-based tests to help in multi-cancer and MRD screening. The company has been actively engaging in M&A to support the development of these new products.